Truist Securities on Vanda Pharmaceuticals (VNDA): EMA news is just 'noise'
Tweet Send to a Friend
Truist Securities analyst Les Sulewski reiterated a Buy rating and $18.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
